List of works - Connie Markulev

210. NEURAPRO: A Multi-center RCT of Omega-3 Polyunsaturated Fatty Acids Versus Placebo in Young People at Ultra-High Risk of Psychotic Disorders: Medium-Term Outcome.

scientific article published on 20 March 2017

22. The Effects of Antidepressant use on Clinical Outcomes in the NEURAPRO-E Trial.

scientific article

Clinical trajectories in the ultra-high risk for psychosis population

scientific article published on 18 February 2018

Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial

scientific article published on 11 March 2020

Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people

scientific article published on 10 July 2019

Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial

scientific article published on 10 June 2020

Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity in first-episode psychosis.

scientific article published on 8 July 2010

Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 y

scientific article

Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.

scientific article

Enhanced cortisol suppression following administration of low-dose dexamethasone in first-episode psychosis patients

scientific article published on 21 November 2012

F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS.

scientific article published in April 2018

Frontal slow wave resting EEG power is higher in individuals at Ultra High Risk for psychosis than in healthy controls but is not associated with negative symptoms or functioning

scientific article published on 06 February 2019

Impaired mismatch negativity to frequency deviants in individuals at ultra-high risk for psychosis, and preliminary evidence for further impairment with transition to psychosis

scientific article published on 10 November 2017

Improving Mood with Physical ACTivity (IMPACT) trial: a cluster randomised controlled trial to determine the effectiveness of a brief physical activity behaviour change intervention on depressive symptoms in young people, compared with psychoeducati

scientific article published on 28 October 2019

NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.

scientific article published on 16 August 2015

Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial

scientific article published on 14 December 2018

O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL.

scientific article

Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis

scientific article published on 06 September 2020

Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis

scientific article

Pilot study evaluating the effect of massage therapy on stress, anxiety and aggression in a young adult psychiatric inpatient unit

scientific article published in May 2008

Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population

scientific article published on 17 June 2020

Relational memory in first episode psychosis: implications for progressive hippocampal dysfunction after illness onset

scientific article published in March 2011

Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial.

scientific article published on 6 June 2019

Relationship between allostatic load and clinical outcomes in youth at ultra-high risk for psychosis in the NEURAPRO study

scientific article published on 16 October 2018

Relationship between vocational status and perceived stress and daily hassles in first-episode psychosis: an exploratory study

scientific article published on 22 November 2012

S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING.

scientific article

S8. RELATIONSHIP BETWEEN ALLOSTATIC LOAD AND POOR FUNCTIONAL CAPACITY IN YOUTH AT ULTRA-HIGH RISK FOR PSYCHOSIS.

scientific article

Stability of retrospective self-reports of childhood trauma in first-episode psychosis

scientific article published on 03 July 2018

Stress hormones and verbal memory in young people over the first 12 weeks of treatment for psychosis.

scientific article

Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis

scientific article published on 09 October 2019

T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION.

scientific article

T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY.

scientific article

The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

scientific article published on 18 September 2019

The effect of atypical antipsychotics on pituitary gland volume in patients with first-episode psychosis: a longitudinal MRI study

scientific article published on January 2010

The impact of neuropsychological functioning and coping style on perceived stress in individuals with first-episode psychosis and healthy controls

scientific article

The relationship between stress, HPA axis functioning and brain structure in first episode psychosis over the first 12 weeks of treatment.

scientific article published on 14 November 2014

The topical niacin sensitivity test: an inter- and intra-rater reliability study in healthy controls

scientific article published on 24 July 2008

Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial

scientific article published on 21 November 2019

Vascular endothelial growth factor and brain-derived neurotrophic factor in quetiapine treated first-episode psychosis

scientific article published on 05 February 2014

List of works by Connie Markulev

210. NEURAPRO: A Multi-center RCT of Omega-3 Polyunsaturated Fatty Acids Versus Placebo in Young People at Ultra-High Risk of Psychotic Disorders: Medium-Term Outcome.

22. The Effects of Antidepressant use on Clinical Outcomes in the NEURAPRO-E Trial.

Clinical trajectories in the ultra-high risk for psychosis population

Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial

Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people

Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial

Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity in first-episode psychosis.

Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 y

Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.

Enhanced cortisol suppression following administration of low-dose dexamethasone in first-episode psychosis patients

F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS.

Frontal slow wave resting EEG power is higher in individuals at Ultra High Risk for psychosis than in healthy controls but is not associated with negative symptoms or functioning

Impaired mismatch negativity to frequency deviants in individuals at ultra-high risk for psychosis, and preliminary evidence for further impairment with transition to psychosis

Improving Mood with Physical ACTivity (IMPACT) trial: a cluster randomised controlled trial to determine the effectiveness of a brief physical activity behaviour change intervention on depressive symptoms in young people, compared with psychoeducati

NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.

Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial

O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL.

Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis

Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis

Pilot study evaluating the effect of massage therapy on stress, anxiety and aggression in a young adult psychiatric inpatient unit

Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population

Relational memory in first episode psychosis: implications for progressive hippocampal dysfunction after illness onset

Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial.

Relationship between allostatic load and clinical outcomes in youth at ultra-high risk for psychosis in the NEURAPRO study

Relationship between vocational status and perceived stress and daily hassles in first-episode psychosis: an exploratory study

S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING.

S8. RELATIONSHIP BETWEEN ALLOSTATIC LOAD AND POOR FUNCTIONAL CAPACITY IN YOUTH AT ULTRA-HIGH RISK FOR PSYCHOSIS.

Stability of retrospective self-reports of childhood trauma in first-episode psychosis

Stress hormones and verbal memory in young people over the first 12 weeks of treatment for psychosis.

Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis

T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION.

T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY.

The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

The effect of atypical antipsychotics on pituitary gland volume in patients with first-episode psychosis: a longitudinal MRI study

The impact of neuropsychological functioning and coping style on perceived stress in individuals with first-episode psychosis and healthy controls

The relationship between stress, HPA axis functioning and brain structure in first episode psychosis over the first 12 weeks of treatment.

The topical niacin sensitivity test: an inter- and intra-rater reliability study in healthy controls

Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial

Vascular endothelial growth factor and brain-derived neurotrophic factor in quetiapine treated first-episode psychosis